Aquarius Surgical Technologies Closes First Tranche of Private Placement

TORONTO, ON / ACCESSWIRE / June 27, 2019 / Aquarius Surgical Technologies Inc. (CSE: ASTI) (“Aquarius” or “the Company”) today has completed the first tranche of a Private Placement announced in the June 13, 2019 Press Release.

The first tranche consists of an offering of 1,446,900 Units at a price of $0.35 per Unit for gross proceeds of $506,415.00. The finder’s fees associated with the transaction were $31,774.05.

Each Unit is comprised of one fully paid common share and one-half of a share purchase warrant. Each whole share purchase warrant entitles the holder to purchase one additional share at a price of $0.70 during the period up to thirty months from the Closing Date of the Placement.

Further Closing of the Private Placement is expected to happen in July 2019 and is subject to all relevant regulatory and other consents and approvals.

Aquarius intends to use the proceeds from the Private Placement for technology development, marketing campaigns and general working capital purposes.

About Aquarius Surgical Technologies Inc.

Aquarius Surgical Technologies Inc. is an exclusive provider of innovative, minimally invasive medical laser systems and consumables for multiple medical disciplines, principally in the field of urology. Solutions comprise multiple laser systems, consumables, clinical education, service, support and maintenance and focus on increasing the availability of services for patients, enhancing the quality of patient care, improving operationally efficiencies and reducing total operational costs.

For more information, please contact:

Gordon Willox, President
Phone: 844-441-9090
Phone: 905-853-9090
gordonwillox@live.ca

Cathy Hume, Investor Relations
Phone: 416-868-1079 x 231
Email: cathy@chfir.com

Neither the CSE Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE Exchange) accepts responsibility for the adequacy or accuracy of this release.

Investors are cautioned that trading in the securities of the Corporation should be considered highly speculative. Except for historical information contained herein, this news release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially. Aquarius Surgical Technologies Inc. will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Aquarius Surgical Technologies Inc.

SOURCE: Aquarius Surgical Technologies Inc.

View source version on accesswire.com:
https://www.accesswire.com/550025/Aquarius-Surgical-Technologies-Closes-First-Tranche-of-Private-Placement

user

Recent Posts

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

3 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

6 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

6 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

6 hours ago